• Explore /
  • Poster
  • / Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.

Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.

Abstract Poster

Authors

null

Tim Meyer

University College London Cancer Institute, London, United Kingdom

Tim Meyer , Daniel H. Palmer , Yee Chao , Caren Choi , Andrzej Deptala , Laetitia Fartoux , Yin-Hsun Feng , Janet Shirley Graham , Julia Hocke , Tae-You Kim , Deng-Yn Lin , Yuk Ting Ma , Markus Peck-Radosavljevic , Paul J. Ross , Baek-Yeol Ryoo , Arne Wenz , Chia-Jui Yen , Arsene-Bienvenu Loembe , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01004003 and NCT00987935

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4074)

DOI

10.1200/jco.2015.33.15_suppl.4074

Abstract #

4074

Poster Bd #

184

Abstract Disclosures

Similar Posters

First Author: Ann-Lii Cheng

First Author: Masatoshi Kudo

First Author: Kazufumi Kobayashi

First Author: Arndt Vogel